Silo Pharma, Inc. (SILO) - 10-K Filing Summary
Business Context and Reporting Period
Company: Silo Pharma, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Silo Pharma is a developmental-stage biopharmaceutical company focused on novel therapeutics for underserved conditions, including PTSD, anxiety, fibromyalgia, Alzheimer's disease, and multiple sclerosis. The company utilizes both conventional drugs and psychedelic formulations (e.g., psilocybin, ketamine).
Key Programs:
- SPC-15: Lead intranasal drug for PTSD and stress-induced anxiety (pre-IND meeting held with FDA in Sept 2024; IND submission targeted for 2025).
- SP-26: Ketamine-based implant for fibromyalgia (preclinical).
- SPC-14: Intranasal compound for Alzheimer's disease (preclinical).
- SPU-16: CNS-homing peptide for multiple sclerosis (preclinical).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $72,102 | $72,102 |
| Net Loss | $(4,392,880) | $(3,700,683) |
| Operating Expenses | $4,771,958 | $3,921,856 |
| Research & Development (R&D) | $2,368,156 | $845,092 |
| Cash & Cash Equivalents | $3,905,799 | $3,524,308 |
| Short-Term Investments | $3,174,724 | $4,140,880 |
| Working Capital | $5,455,483 | $6,905,568 |
| Accumulated Deficit | $(15,264,691) | $(10,871,811) |
Note: Revenue is derived entirely from license fees (Aikido Pharma) recognized over a 15-year term. The company has no history of profitable operations.
Material Changes vs. Prior Period
- Increased R&D Spend: R&D expenses surged 180.2% to $2.37 million, driven by costs associated with Investigator-Sponsored Study Agreements and university research projects (Columbia University, UMB).
- Net Loss Expansion: Net loss increased by $692,197 (18.7%) primarily due to higher operating expenses.
- Capital Raises: The company raised approximately $3.41 million in net proceeds during 2024 through the sale of common stock and pre-funded warrants (June and July 2024 offerings).
- Stock Repurchases: The company repurchased and cancelled 355,710 shares of treasury stock for a total cost of $644,234 during the year.
- Intangible Assets: Recorded $247,400 in intangible assets related to a new exclusive license agreement with Columbia University (effective June 2024).
Guidance, Outlook, Risks, and Contingencies
Outlook & Guidance:
- Management expects R&D activities to increase as product candidates advance.
- Targeting an IND submission for lead candidate SPC-15 in 2025.
- Management believes current cash and short-term investments are sufficient to meet obligations for at least 12 months from the filing date.
Key Risks:
- Capital Requirements: The company has no history of profitable operations and will require additional financing to fund operations and clinical trials. Failure to raise capital could force delays or discontinuation of programs.
- Regulatory & Controlled Substances: Products involve psilocybin (Schedule I) and ketamine (Schedule III). Commercialization depends on FDA approval and potential DEA rescheduling. Regulatory hurdles are significant.
- Clinical Trial Uncertainty: High failure rates in CNS drug development; clinical trials are lengthy, expensive, and outcomes are uncertain.
- Intellectual Property: Reliance on licensed IP from universities (Columbia, UMB); failure to maintain licenses or defend patents could impair competitiveness.
Contingencies:
- Significant future payments are due under sponsored research agreements (approx. $3.3 million due in 2025).
- License agreements with Columbia and UMB include milestone payments and royalty obligations upon commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the ~$7.1 million in liquid assets (cash + short-term investments) against the disclosed $3.3 million in future research commitments and ongoing operating burn rate.
- Regulatory Pathway: Confirm the status of the pre-IND meeting outcomes for SPC-15 and the specific requirements for FDA/DEA approval regarding psilocybin/ketamine formulations.
- Liquidity Events: Review the terms of the June and July 2024 equity offerings, including warrant exercise prices and potential dilution impact.
- License Obligations: Assess the financial impact of the Columbia University license agreement, specifically the $197,400 reimbursement for past patent expenses and future annual fees.
- Internal Controls: Note that while management concluded internal controls were effective as of Dec 31, 2024, a material weakness was identified in 2023 regarding segregation of duties; verify the status of remediation.